STOCKHOLM, Sweden--(BUSINESS WIRE)--Meda (STO:MEDAA) has reached an agreement with the Swiss pharma company Roche to acquire four of their well-established pharmaceutical products. The acquired products have strong brand names and the total sales level is 500 MSEK. No employees will transfer from Roche to Meda in conjunction with the acquisition. Meda acquires world-wide rights to the products and the most important markets are Germany, Spain, Switzerland, USA and France. Meda strengthens its position in key therapy areas; Cardiology, CNS and Pain/Inflammation.
The purchase price is 120 MEUR (approx. 1 125 MSEK), equivalent to about 2 times sales. The acquisition is dependent on antitrust approval.
“I’m glad that we could reach this deal with Roche. The products strengthen our marketing affiliates’ position in key therapy areas. Therefore, good market synergies are expected”, said Anders Lonner, CEO Meda.
The four acquired Roche products are;
Active substance/Medical use/Therapy area
Marcoumar/Phenprocoumon/Anticoagulant/Cardiovascular
Torem/Torasemide/Loop diuretic/Cardiovascular
Tilcotil/Tenoxicam/Rheumatoid and osteoarthritis/Pain/Inflammation
Aurorix/Moclobemide/Antidepressant/Central nervous system (CNS)
Marcoumar (phenprocoumon) is a well-established anticoagulant. This product fits perfectly into Meda’s cardiovascular product portfolio. The largest market is Germany and the total sales level is 200 MSEK.
Torem (torasemide) is a loop diuretic. It is also marketed using trademarks such as Demadex,Dilutol and Toradiur in more than 30 countries – also in the USA and in Japan. The product fits well in Meda’s antihypertensive product range. The sales level is about 180 MSEK.
Tilcotil (tenoxicam) is a NSAID drug for the treatment of painful inflammatory and degenerative disorders of the musculoskeletal system such as rheumatoid and osteoarthritis, and arthrosis. The product is also marketed using the trademarks Mobiflex, Tilatil, Tilcitin and Alganex. Tilcotil fits perfectly into Meda’s therapy area Pain / Inflammation. The sales level is approximately 70 MSEK.
Aurorix (moclobemide) is a MAO-A inhibitor and a well-known antidepressant for specialists to prescribe. Aurorix shows stable market share and a strong patient binding as it is the original brand. The sales level is approximately 50 MSEK.
MEDA AB (publ) is an international specialty pharma company that concentrates on marketing and market-adapted product development. Acquisitions and long-term partnerships are fundamental factors that drive the company’s strategy. Meda is represented with own organisations in 26 countries and with more than 1 500 employees within marketing and sales. Meda’s products are sold in approximately 120 countries world-wide. The Meda share is listed under Large Cap on the OMX Nordic Stock Exchange. Find out more, visit www.meda.se.
This information was brought to you by Cision http://newsroom.cision.com
Contact:
Meda AB
Anders Larnholt, +46 8 630 19 62 or +46 709 458 878
Vice President Investor Relations
anders.larnholt@meda.se
Source: Meda AB